AMENDMENTS TO THE CLAIMS

Listing of Claims

This listing of claims will replace all prior versions, and listing, of claims in the present application.

1. (Currently amended) A method for the treatment ~~or prevention~~ of a disorder wherein said disorder is selected from the group consisting of multiple myeloma, liquid tumor, liver cancer, thymus disorder, T-cell mediated autoimmune disease, endocrinological disorder, ischemia, and neurodegenerative disorder in a mammal comprising administering to said mammal an amount of a human anti-IGF-IR antibody that is effective in treating said disorder.

2. (Withdrawn) The method of claim 1 wherein said liquid tumor is selected from the group consisting of acute lymphocytic leukemia (ALL) and chronic meylogenic leukemia (CML); wherein said liver cancer is selected from the group consisting of hepatoma, hepatocellular carcinoma, cholangiocarcinoma, angiosarcomas, hemangiosarcomas, hepatoblastoma; wherein said thymus disorder is selected from the group consisting of thymoma and thyroiditis, wherein said T-cell mediated autoimmune disease is selected from the group consisting of Multiple Sclerosis, Rheumatoid Arthritis, Systemic Lupus Erythematosus (SLE), Grave's Disease, Hashimoto's Thyroiditis, Myasthenia Gravis, Auto-Immune Thyroiditis, Bechet's Disease, wherein said endocrinological disorder is selected from the group consisting of Type II Diabetes, hyperthyroidism, hypothyroidism, thyroiditis, hyperadrenocorticism, and hypoadrenocorticism; wherein said ischemia is post cardiac ischemia, and wherein said neurodegenerative disorder is Alzheimer's Disease.

3. (Original) The method of claim 1 comprising administering to said mammal said antibody in combination with an agent selected from the group consisting of a corticosteroid, anti-emetic, cancer vaccine, analgesic, anti-vascular agent, and anti-proliferative agent.

4. (Original) The method of claim 1 comprising administering said antibody in combination with an anti-emetic agent, wherein said agent is selected from the group consisting of ondansetron

hydrochloride, granisetron hydrochloride, metroclopramide, domperidone, haloperidol, cyclizine, lorazepam, prochlorperazine, dexamethasone, levomepromazine, or tropisetron.

5. (Original) The method of claim 1 comprising administering said antibody in combination with a vaccine, wherein said vaccine is selected from GM-CSF DNA and cell-based vaccines, dendritic cell vaccines, recombinant viral vaccines, heat shock protein (HSP) vaccines, allogeneic or autologous tumor vaccines.

6. (Original) The method of claim 1 comprising administering said antibody in combination with an analgesic agent, wherein said agent is selected from the group consisting of ibuprofen, naproxen, choline magnesium trisalicylate, or oxycodone hydrochloride.

7. (Original) The method of claim 1 comprising administering said antibody in combination with an anti-vascular agent, wherein said agent is selected from the group consisting of bevacizumab, or rhuMAb-VEGF.

8. (Original) The method of claim 1 comprising administering said antibody in combination with an anti-proliferative agent, wherein said agent is selected from the group consisting of farnesyl protein transferase inhibitors, αvß3 inhibitors, αvß5 inhibitors, p53 inhibitors, and PDGFR inhibitors.

9. (Cancelled)

10. (Original) The method of claim 1 wherein said antibody competes for binding with IGF-IR with an antibody having heavy and light chain amino acid sequences of an antibody selected from the group consisting of 2.12.1, 2.13.2, 2.14.3, 4.9.2, 4.17.3, and 6.1.1.

11. (Cancelled)

12. (Original) The method of claim 11 wherein said antibody comprises a heavy chain comprising the amino acid sequences of CDR-1, CDR-2, and CDR-3, and a light chain comprising the amino acid sequences of CDR-1, CDR-2, and CDR-3, of an antibody selected from the group consisting of 2.12.1, 2.13.2, 2.14.3, 4.9.2, 4.17.3, and 6.1.1.

13. (Cancelled)

14. (Withdrawn) A pharmaceutical composition for the treatment or prevention of a disorder in a mammal comprising an amount of a human anti-IGF-IR antibody that is effective in treating said disorder and a pharmaceutically acceptable carrier, wherein said disorder is selected from the group consisting of multiple myeloma, liquid tumor, liver cancer, thymus disorder, T-cell mediated autoimmune disease, endocrinological disorder, ischemia, and neurodegenerative disorder.

15. (Withdrawn) The pharmaceutical composition of claim 14 further comprising an amount of anti-emetic, cancer vaccine, analgesic, anti-vascular agent, and anti-proliferative agent that, in combination with said antibody, is effective in treating said disorder.

16. (Previously amended) A method of treating a disorder in a mammal comprising administering to said mammal an amount of a human anti-IGF-IR antibody that is effective in treating said disorder, wherein said disorder is multiple myeloma.

17. (Original) A method for the treatment or prevention of aging in a mammal comprising administering to said mammal an amount of an anti-IGF-IR antibody that is effective in said treatment or prevention.